SchizophreniaCreativityMedicinal Chemistry & Drug DevelopmentPsilocybin

Increased Activation of Indirect Semantic Associations under Psilocybin

This early double-blind, placebo-controlled study (1995, n=8) suggests that psilocybin increased indirect semantic priming. The authors add, however, that the setting alone led to a similar effect.

Authors

  • Spitzer, M.
  • Thimm, M.
  • Hermle, L.

Published

Biological Psychiatry
individual Study

Abstract

Hypothesized that psilocybin might exert a defocusing effect on semantic networks (i.e., decrease the signal-to-noise ratio), which should lead to an increased indirect semantic priming effect. A double-blind, placebo-controlled study was conducted on the effects of psilocybin on semantic and indirect semantic priming with 8 normal males (mean age 39.4 yrs). The finding that psilocybin increases indirect semantic priming in normal Ss adds to the general understanding of the effects of hallucinogenic agents on cognitive functions. Data indicate that indirect semantic priming is a highly sensitive measure that appears to respond not only to pharmacologic intervention, but also to the psychological effects of the setting.

Unlocked with Blossom Pro

Research Summary of 'Increased Activation of Indirect Semantic Associations under Psilocybin'

Editorial

βBlossom's Take

This paper is a neat early attempt to measure a cognitive effect that had often been described only anecdotally, namely the widening of associations under psilocybin. Its real value is mixed, because the same task also appears sensitive to setting, but that makes it useful for thinking about how much of psychedelic cognition is drug effect and how much is context.

Introduction

Semantic and indirect semantic priming in lexical decision tasks provide a measure of how activation spreads through semantic networks. Earlier work has shown that thought-disordered schizophrenia is associated with a faster and wider spread of activation, producing increased direct and indirect priming; this pattern has been interpreted as a reduced signal-to-noise ratio in cortical networks that process meaning. Dopaminergic modulation appears to focus semantic processing (increasing the signal-to-noise ratio and reducing spread), whereas psilocybin acts primarily on the serotonin (5-HT) system and is reported anecdotally to ‘‘broaden’’ conscious experience and enhance creativity, suggesting it might have the opposite, defocusing effect on semantic activation. Spitzer and colleagues therefore tested whether psilocybin increases the spread of activation as measured by indirect semantic priming. They conducted a double-blind, placebo-controlled experiment using a lexical decision paradigm to compare direct and indirect semantic priming under psilocybin versus placebo, as part of a larger project on the behavioural and pharmacokinetic effects of the drug.

Methods

A within-subject, double-blind, placebo-controlled design was used: eight healthy male subjects (mean age 39.4 years; seven right-handed, one left-handed; all physicians who provided written informed consent) received a capsule containing 0.2 mg/kg psilocybin or placebo on two testing days at least one week apart, in random order. Testing started at approximately the same time of day (about 11:00 AM). Institutional and national permissions for experimental psilocybin use were obtained. The behavioural task replicated an established lexical decision paradigm. Subjects decided whether a string was a real word. Word pairs of three semantic distances were presented in rapid succession (200 ms): closely related pairs (e.g., "black–white"), indirectly related pairs (e.g., "lemon–sweet"), and unrelated pairs (e.g., "cloud–cheese"). The primary dependent measures were reaction times and error rates for the second word, with semantic priming quantified as both absolute difference scores and as percentage speed gains (priming expressed as percent of baseline speed) to control for general slowing under hallucinogens. Two alternate stimulus versions were used to reduce repetition effects. Each subject performed the paradigm before drug intake and at 50, 150, and 220 minutes after intake; the main statistical comparisons reported in the extract focused on the baseline and 50-minute post-intake timepoint. Statistical analysis included a two-way analysis of variance (intervention: placebo vs psilocybin; time: before vs 50 min) on the indirect priming percentage score, and targeted t-tests assessing significance of priming effects within conditions. Error rates and general reaction-time changes were also examined.

Results

Overall error rates were very low (0–2%) and did not vary systematically with semantic condition or drug. As expected, psilocybin produced a general slowing of reaction times across semantic conditions. Priming was reported both as raw difference scores and as percentage speed gains to account for this global slowing. A two-way ANOVA on the indirect priming percentage score (intervention by time, comparing baseline to 50 minutes) yielded a trend for an effect of time [F(1,7) = 5.09; p = .059], but no significant main effect of intervention and no significant interaction. When the authors tested indirect semantic priming within each intervention separately, they found a nonsignificant increase in indirect priming under placebo but a statistically significant increase under psilocybin [t(7) = 2.82; p = .026]. Direct (closely related) semantic priming showed nonsignificant increases after intake of either placebo or psilocybin, with numerically larger effects under psilocybin. The extract refers to a Table and a Figure illustrating mean reaction times, priming effects, and the difference between psilocybin and placebo runs, but those data are not reproduced in the provided text.

Discussion

Spitzer and colleagues interpret the increased indirect semantic priming under psilocybin as evidence that the drug raises the availability of remote associations, bringing cognitive contents to mind that are normally not activated. They link this effect to the idea of a reduced signal-to-noise ratio in semantic networks under the drug, analogous to earlier interpretations of thought-disordered schizophrenia and contrary to the focusing effect attributed to dopaminergic modulation. The investigators further suggest that the observed increase in indirect priming may reflect a decreased capacity to use contextual information to focus semantic processing, which would explain why subjective reports of broadened consciousness or enhanced creativity can coincide with reductions in objective performance measures. From a methodological standpoint, the authors note that indirect semantic priming is a sensitive measure responsive to both pharmacologic manipulation and to the psychological setting. They offer a post hoc account for the tendency toward increased priming under placebo: subjects were initially anxious and tense, a state associated with stereotyped verbal associations and reduced priming, and tended to relax 30–40 minutes into testing once they inferred whether they had received placebo or psilocybin, which could facilitate broader associative access. The paper reports this as a testable hypothesis and indicates plans to use indirect semantic priming to study nonpharmacological states of anxiety and arousal. Finally, the authors present the finding as an example of linking subjective psychopathology, objective cognitive measurements, and underlying neuromodulatory physiology within a single framework.

Study Details

Cited By (33)

Papers in Blossom that reference this study

Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

13 cited
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation

Johnson, M. W. · Current Topics in Behavioral Neurosciences (2022)

31 cited
Psychedelic Cognition-The Unreached Frontier of Psychedelic Science

Balaet, M. · Frontiers in Neuroscience (2022)

27 cited
LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking

Wießner, I., Falchi, M., Maia, L. O. et al. · Journal of Psychopharmacology (2022)

41 cited
Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow

Maia, L. O., Feilding, A., Ribeiro, S. et al. · Psychopharmacology (2021)

21 cited
Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

78 cited
LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model

Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)

52 cited
The entropic tongue: Disorganization of natural language under LSD

Sanz, C., Pallavicini, C., Carrillo, F. et al. · Consciousness and Cognition (2021)

34 cited
Updating the dynamic framework of thought: Creativity and psychedelics

Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)

139 cited
Show all 33 papers
Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science

Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)

50 cited
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

1128 cited
Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

283 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

518 cited
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

Dimensions of consciousness and the psychedelic state

Bayne, T., Carter, O. · Neuroscience of Consciousness (2018)

151 cited
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

339 cited
Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

184 cited
LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation

Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)

114 cited
90 cited
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation

Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)

181 cited
Perception is in the Details: A Predictive Coding Account of the Psychedelic Phenomenon

Pink-Hashkes, S., Van Rooij, I., Kwisthout, J. · CogSci (2017)

Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

284 cited
Semantic activation in LSD: evidence from picture naming

Family, N., Vinson, D., Vigliocco, G. et al. · Language Cognition and Neuroscience (2016)

53 cited
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

67 cited
Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

118 cited
Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin

Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)

346 cited
96 cited
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)

528 cited
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers

Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)

198 cited
Hallucinogens

Nichols, D. E. · Pharmacology and Therapeutics (2004)

1928 cited
Neurometabolic effects of psilocybin, (MDE) and d-methamphetamine in healthy volunteers

Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O. et al. · Neuropsychopharmacology (1999)

223 cited
Increased Activation of Indirect Semantic... — Research Summary & Context | Blossom